State Employee GLP-1 Coverage by State2026 Data — Dataset Cutoff July 31, 2026

As of July 31, 2026, this state employee GLP-1 coverage by state audit classifies 18 states as offering some obesity-indication coverage, 22 as offering no general obesity coverage, and 10 as plan-dependent or unresolved. Current state-specific official evidence supports 39 of the 50 rows. One additional classification is provisional, and 10 remain unresolved rather than guessed. This count excludes coverage available only for type 2 diabetes, cardiovascular-risk reduction, obstructive sleep apnea, or another non-obesity indication.

Source: Weight Loss Provider Guide Research, state employee GLP-1 coverage audit, dataset version 2026.07.31. Original calculation from the 50-state ledger below.

Here is the part the headline number hides.

Ten of the 18 covered states — 56% — gate the benefit through a managed program or a documented participation requirement. Three current state plans go further and require the covered prescription to come through a designated program provider. Alaska and Maine use Virta Health. Connecticut uses FlyteHealth for eligible adults and a separate Connecticut Children's pathway for eligible younger members.

That is a different benefit from ordinary formulary coverage, and a yes-or-no list cannot show it.

What this page is

This is a 50-state evidence ledger, not a list of drug names found in formularies. It tracks whether state government employees can get obesity-indication medication covered, what conditions apply, when the current rule took effect, how strong the public evidence is, and which official record establishes — or fails to establish — the answer.

A note on terms, because this field uses “GLP-1” as shorthand for more than one drug mechanism:

• Semaglutide and liraglutide are GLP-1 receptor agonists.
• Tirzepatide is a dual GIP and GLP-1 receptor agonist.
• State plans, benefit consultants, and public records routinely group all three under “GLP-1” policy, so this page follows that usage while keeping the pharmacology straight.

The best-known brand pairs also split by indication:

• Wegovy and Ozempic contain semaglutide. Wegovy has chronic-weight-management and certain cardiovascular-risk indications; Ozempic is a diabetes product.
• Zepbound and Mounjaro contain tirzepatide. Zepbound has chronic-weight-management and obstructive-sleep-apnea indications; Mounjaro is a diabetes product.
• Saxenda contains liraglutide for chronic weight management; Victoza contains liraglutide for diabetes.

An indication is the condition for which a drug is approved and covered. The same active ingredient can be covered for one indication and excluded for another under the same plan. That is why “does my plan cover Ozempic?” is rarely enough to answer the obesity-coverage question.

FDA references: Zepbound prescribing information, Wegovy cardiovascular indication, and Zepbound obstructive-sleep-apnea indication.

This is an educational reference, not medical or benefits advice. An individual coverage decision depends on the specific plan, diagnosis, prescription, prior-authorization record, and effective date. The applicable plan administrator's current document governs.

State employee GLP-1 coverage by state: the 2026 results

Eighteen states provide some obesity-indication coverage as of July 31, 2026. Twenty-two provide no general obesity benefit. Ten cannot be resolved into one statewide answer from the public record — usually because plan options differ, the public material does not state the diagnosis-specific rule, or the decisive criteria sit behind a member portal.

Scope: active, non-Medicare employees in each state's principal statewide plan or program. Retirees, Medicaid, Medicare, municipal workers, county workers, university systems, and school employees on separate plans are outside the dataset unless expressly pooled into the same arrangement.

Source: Weight Loss Provider Guide Research, state employee GLP-1 coverage audit, dataset version 2026.07.31, verified July 31, 2026. Scope: active, non-Medicare employees; principal statewide arrangement; obesity indication only. The District of Columbia administers its employee benefits separately and is outside this 50-state dataset.

The 18 states with some obesity coverage

Alaska, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Kansas, Kentucky, Maine, Minnesota, New Jersey, New York, Tennessee, Utah, Virginia, and Wyoming.

All 18 are supported by current state-specific official evidence. “Covered” does not mean unrestricted. It includes a capped Florida program, Utah's limited reimbursement benefit, Delaware's $200 charge, three designated-provider arrangements, multiple mandatory programs, and ordinary prior-authorization designs.

The 22 states with no general obesity coverage

Arkansas, Idaho, Indiana, Louisiana, Maryland, Massachusetts, Michigan, Mississippi, Montana, Nebraska, Nevada, New Hampshire, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, West Virginia, and Wisconsin.

Twenty-one have current state-specific official evidence. Pennsylvania remains Grade B because the current evidence located is an official interstate government report rather than Pennsylvania's own plan document.

Wisconsin is in this column for a date-specific reason. Its benefit begins Jan. 1, 2027. On July 31, 2026, it is still not covered.

The 10 states we would not force into yes or no

Alabama, Arizona, California, Iowa, Missouri, New Mexico, Oklahoma, South Dakota, Vermont, and Washington.

These are not presumed exclusions. In some states, the decisive rule is behind a member login. In others, several carrier arrangements may differ. Washington is the clearest example: the Uniform Medical Plan exclusion is documented, but PEBB offers other plans, so “Washington excludes obesity GLP-1s” would claim more than the source proves.

One recurring trap: the acronym PEBB. Oregon and Washington both use it — Public Employees' Benefit Board in Oregon and Public Employees Benefits Board in Washington. A document that says only “PEBB” is not enough. The state and domain must be checked.

How strong is the evidence behind the 50-state count?

Current state-specific official evidence supports 39 of the 50 classifications, or 78%. One row — Pennsylvania — is provisional. Ten states remain unresolved. The evidence grades are part of the result, not fine print.

Source: Weight Loss Provider Guide Research, dataset version 2026.07.31. Original calculation from the evidence grade assigned to every state row.

The practical rule is simple: Grade C is never converted to “no.” An unknown answer is not an exclusion.

More than half of covered states require a program before or during coverage

Ten of the 18 covered states — 56% — use a managed program or documented participation requirement as part of the obesity-medication benefit. Three require the covered prescription to come through a designated program provider.

Source: Weight Loss Provider Guide Research, dataset version 2026.07.31. Original comparison of current requirements documented in the official state sources linked in the 50-state table.

This is why a bare “18 states cover” line is incomplete. In more than half of the covered states, the plan has made program participation part of the benefit itself.

What counts as coverage in this dataset?

A state is classified as covered only when the evidence supports a benefit for obesity or chronic weight management. Coverage can still carry prior authorization, a mandatory program, a designated provider, an enrollment cap, a clinical threshold, limited reimbursement, or substantial member cost. Those restrictions are disclosed rather than used to erase the benefit.

What does not count

None of the following establishes obesity coverage:

• Ozempic, Mounjaro, or another incretin drug covered only for type 2 diabetes
• Wegovy covered only for its cardiovascular-risk indication
• Zepbound covered only for moderate-to-severe obstructive sleep apnea
• Medicaid coverage or Medicare coverage
• Municipal, county, university, or separate school-employee coverage not pooled into the state arrangement
• A manufacturer coupon, direct-pay price, or cash-pay discount
• A formulary entry that expressly says it does not guarantee diagnosis-specific coverage
• A wellness or weight-management program that does not establish medication coverage
• A future benefit that has not taken effect

Source: Weight Loss Provider Guide Research methodology, dataset version 2026.07.31.

Which states require a designated program prescriber?

Alaska, Connecticut, and Maine do not merely require a member to join a program. Their current documents tie covered weight-management prescriptions to a designated program prescriber. Massachusetts used a similar Vida Health design from January through June 2026, then ended coverage for GLP-1 medications prescribed solely for weight loss on July 1.

Alaska

AlaskaCare states that beginning in 2026, members can fill a weight-loss GLP-1 prescription only when it is written through Virta Health. The rule does not apply in the same way to GLP-1 medication used for diabetes or another covered condition.

Connecticut

Connecticut's May 2026 FlyteHealth FAQ states that weight-loss or weight-management medication is covered when prescribed by a FlyteHealth physician. Follow-up visits are part of the program, and many weight-management medications still require prior authorization. Eligible younger members use a separate Connecticut Children's route.

Maine

Maine states that beginning July 1, 2026, members with weight-loss GLP-1 prescriptions must enroll in Virta and receive the prescription from a Virta provider to maintain coverage. Prescriptions filled outside Virta after the state's Oct. 30 action deadline are not covered.

Massachusetts: a six-month historical case

Massachusetts introduced Vida Health as its weight-management program for 2026, including a designated prescribing route. The GIC then ended obesity-only GLP-1 coverage effective July 1, 2026. Vida continued as a weight-management support program without a covered anti-obesity-medication benefit.

Source: the Alaska, Connecticut, Maine, and Massachusetts official records linked in the 50-state table.

The distinction is narrow but real. “Program required” can mean a member must document coaching while an existing clinician continues to prescribe. “Designated program prescriber” means the covered prescription itself has to come through the plan's program route.

What restrictions do state employee GLP-1 benefits impose?

Coverage rarely means open access. The 18 covered states use different combinations of designated providers, program participation, prior authorization, clinical thresholds, drug preferences, enrollment limits, special coinsurance, and reimbursement caps.

Source: Weight Loss Provider Guide Research, dataset version 2026.07.31. Original classification from the state requirements linked above. States may have additional controls beyond the primary mechanism shown.

Kansas uses a clinical threshold above the adult FDA threshold

The adult FDA weight-management threshold for Wegovy and Zepbound starts at a BMI of 30, or 27 with at least one weight-related condition. Kansas requires a BMI of at least 35 for prescriptions issued or renewed after Jan. 1, 2026.

A member with a BMI of 32 and a qualifying weight-related condition can meet the drug's FDA-labeled population while falling below the Kansas plan threshold. The table's “covered” classification does not erase that gap.

Delaware's $200 charge sits outside the prescription out-of-pocket maximum

Beginning July 1, 2026, Delaware charges $200 for each 30-day supply of a covered weight-management GLP-1 and excludes that charge from the prescription out-of-pocket maximum. Twelve 30-day fills total $2,400 in member charges.

Original calculation from the plan's published charge. Assumes 12 fills and does not include other medical or prescription spending.

Utah provides a reimbursement benefit, not ordinary point-of-sale pharmacy coverage

Utah's July 1, 2026 benefit is easy to misstate. Eligible members complete the program requirements, choose the GLP-1 route instead of bariatric surgery, pay for medication upfront, and seek reimbursement of 50% up to $150 a month for no more than 24 months.

At the monthly cap for all 24 months, the maximum reimbursement is $3,600. The actual benefit remains subject to eligibility, program rules, and the limited program budget.

Original calculation from the published $150 monthly cap and 24-month limit.

What does one official state cost table show?

Virginia's April 2026 State Employee Health Plan presentation provides a reproducible before-and-after cost table for weight-loss GLP-1s across COVA, LODA, and TLC. Reported gross plan cost rose from $53.0 million in plan year 2024 to $128.7 million in plan year 2025 — a 143% increase.

Source: Virginia Department of Human Resource Management, “State Employee Health Plan Update,” April 14, 2026. The subtraction and percentage calculations are by Weight Loss Provider Guide Research.

The gross figure increased 143%. Gross plan cost minus the rebates shown in the same official table increased 177%.

Those calculations do not prove why Virginia or any other state chose a particular benefit design. They show the scale and speed of the spending change in one directly documented state plan without mixing audited figures, press reports, and long-range forecasts from different states.

Which states changed GLP-1 coverage in 2025, 2026, and 2027?

The current roster moved in both directions. Five states ended obesity coverage between July 2025 and July 2026, four expanded or added a benefit, and several kept coverage while changing the access rules. Thirteen of the 15 changes below — 87% — take effect on January 1 or July 1.

Source: Weight Loss Provider Guide Research change log, dataset version 2026.07.31. “Thirteen of 15” is an original calculation from the effective dates shown.

January 1 and July 1 dominate because that is when calendar-year and fiscal-year benefit changes commonly take effect. The current date matters as much as the state name: Wisconsin is “no” during 2026 and is scheduled to become “covered” in 2027.

Why can two state employee GLP-1 coverage counts disagree?

Counts differ when they use different dates, populations, indications, and definitions of coverage.A list that counts diabetes coverage, Medicaid, a future effective date, or one plan option as a statewide rule will not reproduce this dataset.

A national count changes when any of these decisions changes:

• Indication: Does diabetes-only coverage count? It does not here.
• Population: Are Medicaid, retirees, school employees, or local-government workers included? They are not here unless pooled into the principal arrangement.
• Benefit type: Does Utah's limited reimbursement program count? It does here because the employee plan provides a current obesity-medication benefit, and the restriction is disclosed.
• Plan variation: Does one carrier's exclusion become the answer for the entire state? Not when other principal options may differ.
• Evidence age: Does an older interstate survey override a current state document? It does not.
• Effective date: Does an approved 2027 benefit count in 2026? It does not.
• Evidence gap: Does silence mean exclusion? It does not.

The row-level ledger lets another researcher change the definition and recalculate the count without pretending the definition is universal.

What does the state employee GLP-1 coverage data show — and not show?

Coverage is not approval, and a state classification is not an individual benefit determination.

How was the 50-state GLP-1 coverage dataset built?

We reviewed current, publicly accessible state employee benefit guides, agency notices, formularies with diagnosis-specific criteria, prior-authorization documents, board and commission records, procurement documents, plan contracts, court records describing plan terms, and official government coverage reports. The audit ran through July 31, 2026. We classified by indication rather than drug name, and we did not assign a yes or no where the public evidence could not support one.

Source hierarchy

1. A current official plan or state agency rule that explicitly addresses obesity or weight management
2. A current official formulary paired with diagnosis-specific coverage criteria
3. A current official benefit guide, board or commission record, procurement document, plan contract, or court record that states the applicable plan rule
4. A current state-commissioned analysis that explicitly identifies the state public-plan rule
5. An official government cross-state report
6. Secondary reporting used only to locate an original record — not to create a Grade A classification

A lower tier did not override a higher one. An old survey did not override a current state plan. A generic drug policy did not override a state-specific exclusion. A program page did not prove medication coverage unless the document said the medication benefit existed.

The claim ledger

Source: Weight Loss Provider Guide Research methodology, dataset version 2026.07.31.

The reproducibility rule

Each state row publishes:

• the state and principal plan reviewed;
• the classification;
• the restriction or evidence limit;
• the evidence grade;
• the official source;
• the applicable effective date when the source supplies one; and
• enough classification logic for another researcher to reach the same result.

The national totals are original calculations from those 50 rows. No missing state was imputed in either direction.

What are the limitations of this dataset?

Ten states remain unresolved, one row is provisional, and several states offer plan options that do not share one simple rule. Public plan documents can also change, move behind portals, or be replaced during a plan year. The verification date is the boundary of what was checked.

Frequently asked questions about state employee GLP-1 coverage

Title:               State Employee GLP-1 Coverage by State: 2026 Data
Creator:             WPG Research Team
Publisher:           Weight Loss Provider Guide Research
Dataset version:     2026.07.31
Last verified:       2026-07-31
URL:                 https://weightlossproviderguide.com/research/state-employee-glp-1-coverage-by-state/
Geographic coverage: United States — 50 states
Unit of observation: Principal statewide employee health plan; obesity indication only
States classified:   50 (18 covered · 22 no coverage · 10 unresolved)